ATE275956T1 - Veränderung der dns methyltransferase durch kombinationstherapie - Google Patents

Veränderung der dns methyltransferase durch kombinationstherapie

Info

Publication number
ATE275956T1
ATE275956T1 AT99953211T AT99953211T ATE275956T1 AT E275956 T1 ATE275956 T1 AT E275956T1 AT 99953211 T AT99953211 T AT 99953211T AT 99953211 T AT99953211 T AT 99953211T AT E275956 T1 ATE275956 T1 AT E275956T1
Authority
AT
Austria
Prior art keywords
alteration
combination therapy
dna methyltransferase
relates
gene
Prior art date
Application number
AT99953211T
Other languages
English (en)
Inventor
Jeffrey M Besterman
Alan Robert Macleod
William M Siders
Original Assignee
Methylgene Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Methylgene Inc filed Critical Methylgene Inc
Application granted granted Critical
Publication of ATE275956T1 publication Critical patent/ATE275956T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • C12N15/1137—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y201/00—Transferases transferring one-carbon groups (2.1)
    • C12Y201/01—Methyltransferases (2.1.1)
    • C12Y201/01045—Thymidylate synthase (2.1.1.45)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y203/00—Acyltransferases (2.3)
    • C12Y203/01—Acyltransferases (2.3) transferring groups other than amino-acyl groups (2.3.1)
    • C12Y203/01048—Histone acetyltransferase (2.3.1.48)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/31—Chemical structure of the backbone
    • C12N2310/315—Phosphorothioates
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/32—Chemical structure of the sugar
    • C12N2310/321—2'-O-R Modification
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/34—Spatial arrangement of the modifications
    • C12N2310/341—Gapmers, i.e. of the type ===---===
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/34—Spatial arrangement of the modifications
    • C12N2310/346—Spatial arrangement of the modifications having a combination of backbone and sugar modifications

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Engineering & Computer Science (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Biomedical Technology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Biochemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Biotechnology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Molecular Biology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Microbiology (AREA)
  • Biophysics (AREA)
  • Virology (AREA)
  • Plant Pathology (AREA)
  • Epidemiology (AREA)
  • Physics & Mathematics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
AT99953211T 1998-10-19 1999-10-19 Veränderung der dns methyltransferase durch kombinationstherapie ATE275956T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US10480498P 1998-10-19 1998-10-19
PCT/US1999/024278 WO2000023112A1 (en) 1998-10-19 1999-10-19 Modulation of gene expression by combination therapy

Publications (1)

Publication Number Publication Date
ATE275956T1 true ATE275956T1 (de) 2004-10-15

Family

ID=22302488

Family Applications (1)

Application Number Title Priority Date Filing Date
AT99953211T ATE275956T1 (de) 1998-10-19 1999-10-19 Veränderung der dns methyltransferase durch kombinationstherapie

Country Status (8)

Country Link
EP (1) EP1123111B1 (de)
JP (1) JP2002528391A (de)
AT (1) ATE275956T1 (de)
AU (1) AU766084B2 (de)
CA (1) CA2347003A1 (de)
DE (1) DE69920247T2 (de)
ES (1) ES2228119T3 (de)
WO (1) WO2000023112A1 (de)

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2003500052A (ja) * 1999-05-03 2003-01-07 メチルジーン インコーポレイテッド ヒストン脱アセチル酵素の抑制
EP1438404A2 (de) * 2000-03-24 2004-07-21 Methylgene, Inc. Hemmung von spezifischen isoformen der histondeacetylase
PE20020354A1 (es) 2000-09-01 2002-06-12 Novartis Ag Compuestos de hidroxamato como inhibidores de histona-desacetilasa (hda)
CA2434601A1 (en) * 2001-01-12 2002-09-12 Methylgene, Inc. Methods for specifically inhibiting histone deacetylase-4
US6905669B2 (en) 2001-04-24 2005-06-14 Supergen, Inc. Compositions and methods for reestablishing gene transcription through inhibition of DNA methylation and histone deacetylase
GB2392911A (en) * 2001-05-11 2004-03-17 Methylgene Inc Inhibitors of dna methyltransferase isoforms
US6706686B2 (en) 2001-09-27 2004-03-16 The Regents Of The University Of Colorado Inhibition of histone deacetylase as a treatment for cardiac hypertrophy
AU2002340253C1 (en) 2001-10-16 2011-03-31 Sloan-Kettering Institute For Cancer Research Treatment of neurodegenerative diseases and cancer of the brain
EP1482962A4 (de) * 2002-02-15 2009-12-23 Sloan Kettering Inst Cancer Verfahren zur behandlung von trx-vermittelten erkrankungen
US6982253B2 (en) 2002-06-05 2006-01-03 Supergen, Inc. Liquid formulation of decitabine and use of the same
WO2004031408A1 (en) * 2002-09-30 2004-04-15 F.Hoffmann-La Roche Ag Oligonucleotides for genotyping thymidylate synthase gene
EP1578764A4 (de) * 2002-10-21 2007-01-10 Univ New Jersey Med Thymidylatsynthasepolymorphismen zur verwendung beim screening auf krebsrisiko
JP4543188B2 (ja) * 2004-03-10 2010-09-15 学校法人日本医科大学 ヒトチミジル酸合成酵素に対するＲＮＡｉとして作用するＲＮＡ配列
US7250416B2 (en) 2005-03-11 2007-07-31 Supergen, Inc. Azacytosine analogs and derivatives
US7700567B2 (en) 2005-09-29 2010-04-20 Supergen, Inc. Oligonucleotide analogues incorporating 5-aza-cytosine therein
DK2198042T3 (en) * 2007-09-17 2017-01-23 Mdxhealth Sa New markers for bladder cancer detection
EP2750768B1 (de) 2011-08-30 2018-10-03 Astex Pharmaceuticals, Inc. Decitabin-derivat zubereitungen
EP3470536A1 (de) 2013-10-01 2019-04-17 The J. David Gladstone Institutes Zusammensetzungen, systeme und verfahren zum wirkstoffscreening auf genexpressionsrauschen und verwendungen davon
JP6768722B2 (ja) 2015-07-02 2020-10-14 大塚製薬株式会社 凍結乾燥医薬組成物
AU2018310857A1 (en) 2017-08-03 2020-02-13 Otsuka Pharmaceutical Co., Ltd. Drug compound and purification methods thereof
US20190374656A1 (en) * 2018-06-11 2019-12-12 Aether Therapeutics Inc. Methods for maintaining optimum dna methylation by endogenous methylation and demethylation of dna
US11938143B2 (en) * 2021-10-19 2024-03-26 Akirabio, Inc. Compositions comprising 2′-deoxycytidine analogs and use thereof for the treatment of sickle cell disease, thalassemia, and cancers

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1994008625A1 (en) * 1992-10-21 1994-04-28 Temple University - Of The Commonwealth System Of Higher Education Combination of antineoplastic agent and antisense oligonucleotides for treatment of cancer
US5744460A (en) * 1996-03-07 1998-04-28 Novartis Corporation Combination for treatment of proliferative diseases
WO1997032604A1 (en) * 1996-03-07 1997-09-12 Novartis Ag Antiproliferative combinations, containing raf-targeted oligonucleotides and chemotherapeutic compounds

Also Published As

Publication number Publication date
AU6519499A (en) 2000-05-08
EP1123111B1 (de) 2004-09-15
AU766084B2 (en) 2003-10-09
JP2002528391A (ja) 2002-09-03
WO2000023112A1 (en) 2000-04-27
ES2228119T3 (es) 2005-04-01
EP1123111A1 (de) 2001-08-16
CA2347003A1 (en) 2000-04-27
WO2000023112A9 (en) 2000-08-31
DE69920247D1 (de) 2004-10-21
DE69920247T2 (de) 2005-09-29

Similar Documents

Publication Publication Date Title
ATE275956T1 (de) Veränderung der dns methyltransferase durch kombinationstherapie
AU2001290706A1 (en) Antisense modulation of clusterin expression
DE69403642D1 (de) 7-deazapurin modifizierte oligonukleotide
CY1116385T1 (el) Αντινοηματικη διαμορφωση της εκφρασης της απολιποπρωτεινης β
ATE334657T1 (de) Hemmung der bcl-2 protein expression durch liposomale antisense-oligodeoxynukleotide
EP1131465A4 (de) Antisense-modulierung der interleukin-15 expression
DK1104303T3 (da) Carbohydrat eller 2 ´ -modificerede oligonukleotider med alternerende internukleosidbindinger
HK1026229A1 (en) Modified dorsal tissue affecting factor and compositions
EP1117672A4 (de) Antisense-modulation der survivin-expression
EP1135402A4 (de) Antisense modulation der egr-1 expression
WO2003054154A3 (en) Antisense modulation of mucin 1, transmembrane expression
WO2004016754A3 (en) ANTISENSE MODULATION OF Nav1.3 EXPRESSION
WO2001029175A3 (en) Antisense modulation of fra-1 expression
WO2003099215A3 (en) Antisense modulation of glucocorticoid receptor expression
EP1248633A4 (de) Antisense-modulation der expression von glycogen-synthase kinase 3 beta
EP1235924A4 (de) Antisense modulation der rank expression
AU2606000A (en) Antisense modulation of x-linked inhibitor of apoptosis expression
BR0313550A (pt) modulação "antisense" da expressão de sintetase 1 de acil-coa
WO2000061786A3 (en) Antisense modulation of pdk-1 expression
EP1243289A3 (de) Veränderung der Genexpression durch Kombinationstherapie
WO2001062911A3 (en) Antisense and catalytically acting nucleic acid molecules targeted to grb2- related with insert domain (grid) proteins and their uses
WO2002041836A3 (en) Antisense modulation of src-1 expression
WO2003050247A3 (en) Antisense modulation of mhc class ii transactivator expression
WO2002097108A3 (en) Antisense modulation of dual specific phosphatase 5 expression
WO2003105754A3 (en) ANTISENSE MODULATION OF VASCULAR ENDOTHELIAL GROWTH FACTOR B (VEGF-B) EXPRESSION

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 1123111

Country of ref document: EP

REN Ceased due to non-payment of the annual fee